Overdose mortality is reducing the gains in life expectancy of antiretroviral-treated people living with HIV in British Columbia, Canada-Reference-Cited by-同舟云学术

Overdose mortality is reducing the gains in life expectancy of antiretroviral-treated people living with HIV in British Columbia, Canada

Published:2021-10 Issue: Volume:96 Page:103195
ISSN:0955-3959
Container-title:International Journal of Drug Policy
language:en
Short-container-title:International Journal of Drug Policy

Author:

St-Jean Martin,Dong Xinzhe,Tafessu Hiwot,Moore David,Honer William G.,Vila-Rodriguez Fidel,Sereda Paul,Hogg Robert S.,Patterson Thomas L.,Salters Kate,Barrios Rolando,Montaner Julio S.G.,Lima Viviane D.

Funder

Canadian Foundation for AIDS Research

Canadian Institutes of Health Research

Publisher

Elsevier BV

Subject

Health Policy,Medicine (miscellaneous)

Reference50 articles.

1. Why the FUSS (Fentanyl Urine Screen Study)? A cross-sectional survey to characterize an emerging threat to people who use drugs in British Columbia, Canada;Amlani;Harm Reduction Journal,2015

2. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies;Antiretroviral Therapy Cohort;Lancet,2008

3. United States life tables eliminating certain causes of death, 1999-2001;Arias;National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System,2013

4. Introduction to the analysis of survival data in the presence of competing risks;Austin;Circulation,2016

5. An integrated approach to cause-of-death analysis: Cause-deleted life tables and decompositions of life expectancy;Beltran-Sanchez;Demographic Research,2008

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Longitudinal evolution of the HIV effective reproduction number following sequential expansion of treatment as prevention and pre-exposure prophylaxis in British Columbia, Canada: a population-level programme evaluation;The Lancet HIV;2024-07

2. Characterizing opioid agonist therapy uptake and factors associated with treatment retention among people with HIV in British Columbia, Canada;Preventive Medicine Reports;2023-10

3. Living longer with HIV: gains for some but not for all;The Lancet HIV;2023-05

4. Dynamics of overdose and non-overdose mortality among people living with HIV amidst the illicit drug toxicity crisis in British Columbia;AIDS Care;2023-04-24

5. Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs;International Journal of Drug Policy;2021-10